ESC 365 - Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

Session: Recent advances in diagnosis/treatment of hypertension

Topic: Target Organ Damage/Left Ventricular Hypertrophy

Speaker: Doctor P. Kolkhof (Wuppertal, DE)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Peter Kolkhof

BAYER AG, R&D Pharmaceuticals, Wuppertal (Germany)

0 follower

3 more presentations in this session

Potential therapeutic efficacy via avB3-integrin dependent interaction of developmental endothelial locus-1 (Del-1) after established angiotensin-II dependent hypertension

Speaker: Mr M. Amponsah-Offeh (Mannheim, DE)

Protective effects of renal denervation based on MRI assessment of the brain in patients with resistant hypertension

Speaker: Doctor A. Sukhareva (Tomsk, RU)

24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension

Speaker: Associate Professor D. Maximkin (Moscow, RU)

Access the full session

Recent advances in diagnosis/treatment of hypertension

Speakers: Doctor P. Kolkhof, Mr M. Amponsah-Offeh, Doctor A. Sukhareva, Associate Professor D. Maximkin

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources